Efficacy of ximelagatran for secondary stroke prevention in atrial fibrillation: Pooled analysis of the SPORTIF III and V clinical trial results

被引：0

作者：

Akins, P

Zoble, R

Haley, JA

Feldman, H

Newman, D

Spitzer, SG

Ding, PY

Diener, HC

Albers, GW

机构：

[1] Mercy Stroke Ctr, Sacramento, CA USA

[2] James A Haley VAMC, Tampa, FL USA

[3] Nova SE Univ, Ft Lauderdale, FL 33314 USA

[4] Univ Toronto, Markham, ON, Canada

[5] Praxisklin Herz & Gelasse Dresden, Dresden, Germany

[6] Taipei Vet Gen Hosp, Taipei, Taiwan

[7] Univ Essen Gesamthsch, Essen, Germany

[8] Stanford Stroke Ctr, Palo Alto, CA USA

来源：

STROKE | 2005年 / 36卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：423 / 423

页数：1

共 50 条

[1] Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation - Pooled analysis of SPORTIF III and V clinical trials
Akins, Paul T.
Feldman, Harvey A.
Zoble, Robert G.
Newman, David
Spitzer, Stefan G.
Diener, Hans-Christoph
Albers, Gregory W.
[J]. STROKE, 2007, 38 (03) : 874 - 880
[2] Stroke prevention in atrial fibrillation: Pooled analysis of SPORTIF III and V trials
Albers, GW
[J]. AMERICAN JOURNAL OF MANAGED CARE, 2004, 10 (14): : S462 - S469
[3] Stroke prevention with the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation: Pooled analysis of the SPORTIF III and V trials
Petersen, P.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 29 - 29
[4] Stroke prevention with the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation: final results of the pooled analysis of the SPORTIF III and V trials
Olsson, SB
[J]. EUROPEAN HEART JOURNAL, 2004, 25 : 643 - 643
[5] Pooled analysis of the SPORTIF III and V Trials: Secondary stroke prevention and stroke subtypes
Albers, GW
[J]. STROKE, 2004, 35 (06) : E199 - E199
[6] Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation - Pooled analysis from the SPORTIF III and V studies
Diener, HC
[J]. CEREBROVASCULAR DISEASES, 2006, 21 (04) : 279 - 293
[7] Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation (SPORTIF V)
[J]. CIRCULATION, 2003, 108 (21)
[8] Ximelagatran is noninferior of warfarin for prevention of strokes and systemic embolic events in patients with atrial fibrillation: SPORTIF V results
Trifonov, IP
[J]. KARDIOLOGIYA, 2004, 44 (01) : 73 - 74
[9] Outcomes for Ximelagatran compared with warfarin according to INR control: Results from SPORTIF III and V atrial fibrillation trials
Kaatz, S
White, HD
Gruber, M
Albers, GW
[J]. BLOOD, 2005, 106 (11) : 265A - 265A
[10] Ximelagatran, an oral direct thrombin inhibitor, compared with dose-adjusted warfarin for primary and secondary stroke prevention in patients with atrial fibrillation (SPORTIF V)
Albers, GW
[J]. STROKE, 2004, 35 (01) : 242 - 243

← 1 2 3 4 5 →